GlassScriptPhysician profile
Nastaran Safdarian
NPI 1144414434
$10,202.84
in general payments reported to CMS, 2019-2025
38 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,080 · 2021: $1,096 · 2022: $1,421 · 2023: $1,707 · 2024: $1,746 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,195 · Education: $223 · Consulting Fee: $26.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,195.45 |
| Education | $222.83 |
| Consulting Fee | $26.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,392.34 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,227.91 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $920.56 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $849.55 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Genzyme Corporation | $567.46 | 2019-2025 | |
| Octapharma USA, INC. | $557.64 | 2019-2025 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
| Grifols USA, LLC | $546.14 | 2019-2024 | Xembify, Gamunex-C |
| Novo Nordisk INC | $525.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $466.11 | 2019-2025 | |
| Genentech USA, INC. | $437.49 | 2021-2025 | Xolair |
| Amgen INC. | $333.13 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $291.17 | 2022-2025 | Orladeyo |
| Alk-Abello, INC | $230.81 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Leo Pharma INC. | $193.84 | 2022-2025 | Adbry |
| Optinose US, INC. | $193.57 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $184.97 | 2020-2025 | Hizentra, Privigen |
| Pharming Healthcare, INC. | $175.37 | 2023-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $154.90 | 2023-2024 | |
| Kaleo, INC. | $134.19 | 2020-2024 | Auvi-Q |
| Pfizer INC. | $125.12 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $113.76 | 2019-2022 | |
| Blueprint Medicines Corporation | $74.52 | 2023-2024 | Ayvakit |
| Adma Biomanufacturing LLC | $73.51 | 2022-2024 | |
| Azurity Pharmaceuticals, INC. | $63.13 | 2025 | Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.19 | 2020-2021 | |
| Covis Pharma Gmbh | $38.98 | 2022 | |
| Organon LLC | $36.54 | 2025 | |
| Phadia US INC. | $35.15 | 2019-2024 | Immunocap |
| Lilly USA, LLC | $26.06 | 2025 | Ebglyss |
| Greer Laboratories, INC. | $25.85 | 2024 | Palforzia |
| Kedrion Biopharma, INC. | $24.37 | 2025 | Gammaked, Kedrab, Koate |
| Insmed, INC. | $22.11 | 2025 | Arikayce |
| Shire North American Group INC | $21.59 | 2019 | |
| Merck Sharp & Dohme LLC | $20.41 | 2023 | |
| Hospira, INC. | $18.55 | 2024 | |
| Hikma Pharmaceuticals USA | $18.46 | 2023 | Ryaltris |
| Gc Biopharma USA, INC. | $17.63 | 2025 | Alyglo |
| Ionis Pharmaceuticals, INC. | $17.05 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nastaran Safdarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.